Predictive value of antinuclear autoantibodies: The lessons of the systemic sclerosis autoantibodies

Koenig, Martial; Dieudé, Mélanie; Senécal, Jean‐Luc

doi:10.1016/j.autrev.2008.06.010

Cited by 104 publications

(77 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimation of the worldwide prevalence of anti-RNAP III in SSc (Figure 4) is challenging because published studies include different sample sizes and use different methodologies. The estimated pooled prevalence of anti-RNAP III was 11% (95% CI 8-14%), in accordance with the estimation made by Koenig et al in their study of 4,672 patients from different countries (44). In comparison, prevalence of ACA was estimated at 26% in that same study, and at 33% in the 2003 American College of Rheumatology guidelines for antibody testing in SSc (45).…”

Section: Prevalence Of Anti-rnap III In Ssc 413supporting

confidence: 88%

“…In comparison, prevalence of ACA was estimated at 26% in that same study, and at 33% in the 2003 American College of Rheumatology guidelines for antibody testing in SSc (45). Prevalence of anti-topo I was estimated at between 20 and 29% (44,45). Antifibrillarin (U3 RNP) antibodies are found in 4-10% of SSc patients, anti-U1 RNP antibodies in 6%, anti-PM-Scl in 4-11%, and antiTh/To antibodies in 2-5% (18).…”

Section: Prevalence Of Anti-rnap III In Ssc 413mentioning

confidence: 86%

“…Anti-RNAP III has been associated with the diffuse cutaneous form of SSc and renal crisis (1,19,44). ILD seems to be less prevalent in this group of patients (19).…”

Section: Prevalence Of Anti-rnap III In Ssc 413mentioning

confidence: 93%

See 2 more Smart Citations

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Sobanski

Dauchet

Lefèvre

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Studies assessing the prevalence of anti-RNA polymerase III (anti-RNAP III) antibodies in systemic sclerosis (SSc) have yielded a wide range of results. The aim of the present study was to describe a new SSc cohort tested for presence of anti-RNAP III and perform a systematic review and meta-analysis to assess the prevalence of anti-RNAP III in patients worldwide and the potential factors of variability.Methods. Seropositivity for anti-RNAP III was evaluated in a French cohort of SSc patients. A systematic review of the literature was carried out in PubMed and EMBase. Meta-analysis was performed using available data on prevalence, clinical characteristics of SSc patients, and the types of assays used for anti-RNAP III testing.Results. One hundred thirty-three French SSc patients were tested for anti-RNAP III, and a prevalence of 6-9% was found in these patients. Thirty studies representing a total population of 8,437 SSc patients were included in the meta-analysis. Prevalence of anti-RNAP III in this population was highly variable (range 0-41%). The overall pooled prevalence of anti-RNAP III was 11% (95% confidence interval 8-14), but heterogeneity was high among studies (I 2 ‫؍‬ 93%, P < 0.0001). Geographic factors such as continent or country of study origin partially explained this heterogeneity and correlated with the prevalence. No other baseline SSc characteristics were significantly correlated with the prevalence of anti-RNAP III.Conclusion. Data on our new cohort and our meta-analysis of the literature confirmed that anti-RNAP III prevalence in SSc varies among centers. Geographic factors were significantly associated with prevalence, which underscores the probable implication that genetic background and environmental factors play a role. Heterogeneity among studies remained largely unexplained.

show abstract

Section: Prevalence Of Anti-rnap III In Ssc 413supporting

confidence: 88%

Section: Prevalence Of Anti-rnap III In Ssc 413mentioning

confidence: 86%

See 1 more Smart Citation

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Sobanski

Dauchet

Lefèvre

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although the pathogenesis of SSc remains unknown, systemic autoimmunity is one of the central features of SSc, since antinuclear antibodies (Abs) are detected in more than 90% of SSc patients [1][2][3][4]. SSc patients have autoantibodies that react to various intracellular components, such as DNA topoisomerase I, centromere, RNA polymerases, U1RNP, U3RNP, Th/To, and histones [1][2][3][4]. Although it remains controversial whether these SSc-specific autoantibodies directly contribute to the clinical manifestations of SSc, autoantibodies against several intracellular and extracellular enzymes, including one of the antioxidant enzymes peroxiredoxin and matrix metalloproteinases, may play a pathogenetic role [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

et al. 2009

View full text Add to dashboard Cite

Objective: To determine the presence or levels of antibodies (Abs) against caspase-3 and their clinical relevance in systemic sclerosis (SSc).Methods: Anti-caspase-3 Ab was examined by enzyme-linked immunosorbent assay and immunoblotting.Results: IgG anti-caspase-3 Ab levels in SSc patients were higher than in normal controls.SSc patients positive for IgG anti-caspase-3 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-caspase-3 Ab levels correlated positively with serum IgG levels, renal vascular resistance, and serum levels of 8-isoprostane.Immunoblotting analysis confirmed the presence of anti-caspase-3 Ab in sera from SSc patients. Caspase-3 enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-caspase-3 Ab. Conclusion:These results suggest that autoantibody against caspase-3 is generated in SSc and that this Ab is related to the severity of pulmonary fibrosis, vascular damage, and inflammation.

show abstract

Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy

Benveniste

Drouot

Jouen

et al. 2011

Arthritis & Rheumatism

189

132

View full text Add to dashboard Cite

Objective. Anti-signal recognition particle (anti-SRP) autoantibodies are associated with severe acquired necrotizing myopathies. The role of these autoantibodies remains elusive, and the evolution of anti-SRP levels over time is unknown. In this study, we developed an addressable laser bead immunoassay (ALBIA) technique to investigate a correlation between anti-SRP levels, serum creatine kinase (CK) levels, and muscle strength in patients with necrotizing myopathy.Methods. The diagnostic value of the ALBIA assay was determined by comparing serum levels of anti-SRP autoantibodies in 31 anti-SRP immunodotpositive patients to those in 190 healthy blood donors and 199 control patients with different inflammatory/ autoimmune conditions or polyclonal hypergammaglobulinemia. Among the 31 anti-SRP-positive patients, serum samples from 8 patients were monitored over time for levels of anti-SRP autoantibodies and levels of CK (determined at least 3 times, consecutively, over a mean followup period of 783 days). The relationship between levels of anti-SRP autoantibodies and levels of CK was tested using a linear mixed model.Results. The assay yielded positive results for anti-SRP in all anti-SRP immunodot-positive serum samples tested, while all control sera tested negative. The 8 anti-SRP-positive patients who were followed up longitudinally were found to have normalized CK levels and improved muscle strength. There was a striking correlation between the degree of myolysis, as measured by CK levels, in patients receiving therapy and the anti-SRP54 autoantibody levels in these same patients (P ‫؍‬ 0.002).Conclusion. Anti-SRP-positive myositis appears to be one of the few autoimmune diseases in which specific autoantibody levels are correlated with surrogate disease activity markers. These results reveal the usefulness of monitoring anti-SRP autoantibody levels in patients receiving therapy, and may also suggest a possible pathogenic role for anti-SRP autoantibodies in the necrotizing myopathies.Autoantibodies directed against signal recognition particles (anti-SRP) are present in a minority (4-6%) of patients with acquired inflammatory and/or necrotizing myopathies (1-5). Anti-SRP autoantibodies are generally associated with severe clinical forms of the disease, particularly those with heart and lung involvement (6,7) and resistance to steroid therapy (8-10).

show abstract

Predictive value of antinuclear autoantibodies: The lessons of the systemic sclerosis autoantibodies

Cited by 104 publications

References 27 publications

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis

Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy

Contact Info

Product

Resources

About